Merck taps 4D pharma for bacterial vaccine R&D project

Merck has teamed up with 4D pharma to develop bacterial strains as vaccines. The deal gives Merck the chance to pick up three candidates against undisclosed indications for an upfront fee and up to $347.5 million (€316.2 million) in milestones.